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1. Introduction 
Ticks are the most important vectors of emerging and re-emerging diseases of 
pets, many of which are potentially transmissible to humans (Glickman et al., 
2006; Beugnet and Marié, 2009). Tick species such as Rhipicephalus 
sanguineus, Ixodes scapularis, Ixodes ricinus and Dermacentor reticulatus 
infest humans and pets and transmit disease-causing pathogens such as 
Borrelia spp. (Lyme disease and various borreliosis), TBEV (tick-borne 
encephalitis), Anaplasma phagocytophilum (human and canine anaplasmosis), 
Francisella tularensis (tularemia), Rickettsia spp. (human and animal 
rickettsiosis), OHFV (Omsk hemorrhagic fever), Babesia canis (canine 
babesiosis), and Ehrlichia canis (canine monocytic ehrlichiosis) (de la Fuente et 
al., 2008; Beugnet and Marié, 2009). Other arthropods such as mosquitoes, 
fleas and sand flies also transmit vector-borne diseases (VBD) affecting 
humans and pets (Day, 2011; Beugnet and Marié, 2009). Vector-borne 
infectious diseases of pets and humans are emerging or re-emerging as a result 
of ineffective control programs, demographic and societal changes and 
increasing acaricide/insecticide and drug resistance (Glickman et al., 2006). 
Vaccines have not been developed or successfully implemented for most VBD 
affecting humans and pets (Day, 2011). Therefore, control of arthropod vectors 
is important for the eradication of VBD (de la Fuente and Kocan, 2003; 
Speranc¸ a and Capurro, 2007; Karunamoorthi, 2011; Coller et al., 2012). 
 
2. Vaccines for the control of arthropod vectors and vector-borne pathogens 
Vaccination is an environmentally friendly alternative for the control of vector 
infestations and pathogen infections that allows control of several VBD by 
targeting their common vector (de la Fuente and Kocan, 2003, 2006; Willadsen, 
2004; de la Fuente et al., 2007, 2011). The hypothesis behind vaccine action is 
that ectoparasites feeding on immunized hosts ingest antibodies specific for the 
target antigen that could reduce their levels and biological activity and/or 
interact with conserved epitopes in other proteins resulting in reduced feeding, 
developmental and reproductive performance, with a possible reduction in 
vector capacity (de la Fuente et al., 2006a, 2006b, 2011; Merino et al., 2011a, 
2011b; Moreno-Cid et al., 2011, 2013; Bensaci et al., 2012). Therefore, the 
greatest vaccine effect is in the reduction of larval infestations in subsequent 
generations, which results in the reduction of ectoparasite populations and thus 
the exposure of susceptible hosts to vector infestations and VBD (de la Fuente 
et al., 2007). The limiting step in the development of tick vaccines is the 
identification of protective antigens (de la Fuente and Kocan, 2003). However, 
recent results have shown that it is possible to use vector protective antigens for 
the control of arthropod vector infestations and pathogeninfection (de la Fuente 
and Kocan, 2003, 2006; Willadsen, 2004; de la Fuente et al., 2006a, 2006b, 
2007, 2011; Merino et al., 2011a, 2011b; Moreno-Cid et al., 2011, 2013; 
Bensaci et al., 2012; de la Fuente and Merino, 2013). 
 
 
3. Vaccines for the control of arthropod vectors of pets  
The growing interaction between pets and people underlines the importance of 
developing new interventions for themonitoring and control ofVBD (Glickman et 
al., 2006). However, very little progress has been made for the control of 
ectoparasite infestations and VBD of pets using vaccination with vector 
protective antigens. Recent developments in both ticks and tick-borne pathogen 
genomics and the study of tick-pathogen and tick-host interactions have 
advanced our understanding of the genetic factors and molecular pathways 
involved at the host-vector-pathogen interface (de la Fuente and Estrada-Peña, 
2012; de la Fuente, 2012). These technologies are generating extensive 
information and suggested candidate protective antigens for the control of tick 
infestations affecting pets and humans (e.g. for R. sanguineus, Trimnell et al., 
2005; Anatriello et al., 2010; Villar et al., 2010; Vancová et al., 2010; Rodríguez-
Mallon et al., 2012). However, only three publications have reported results on 
vaccination trials in pets using vector protective antigens for the control of 
ectoparasite infestations. As discussed bellow, these trials were conducted on 
the most relevant host-tick model in dogs for the control of R. sanguineus 
infestations using three different antigen preparations,tick gut protein extract, 
Subolesin/akirin (SUB/AKR) and Bm86 (Szabó and Bechara, 1997; Canales et 
al., 2009; Perez-Perez et al., 2010). 
3.1 Tick gut protein extract: The pioneering work of Allen and Humphreys 
(1979) demonstrated the feasibility of controlling tick infestations using vector 
protein extracts. Szabó and Bechara (1997) used this principle to demonstrate 
control of R. sanguineus infestations in dogs vaccinated with tick gut protein 
extracts. The most significant effect obtained in ticks fed on immunized dogs 
was the reduction in the number of ticks that laid eggs, thus showing a 
significant effect of the vaccine on reducing oviposition. Reduction in tick 
oviposition is one of the most important effects obtained with tick vaccines 
thatimpact on reducing tick populations in the field (de la Fuente and Kocan, 
2003, 2006; Willadsen, 2004; de la Fuente et al., 2007).  
3.2 Subolesin/akirin: SUB, initially named 4D8, was discovered as a tick 
protective antigen in a mouse model of I. scapularis infestations. SUB is the 
ortholog protein of insect AKR that have a broad function as transcription 
factors explaining the profound effect of gene knockdown by RNA interference 
(RNAi) on tick and insect physiology, as well as on development and gene 
expression in ticks (de la Fuente et al., 2006b, 2011). SUB/AKR are functionally 
important for arthropod immunity to pathogens and, at least in ticks for other 
molecular pathways, including those required for tissue development and 
function and for pathogen infection and multiplication (de la Fuente et al., 2011). 
SUB gene knockdown by RNAi resulted in sterile female and male ticks and 
was proposed as a method for tick autocidal control (de la Fuente et al., 2006c; 
Merino et al., 2011a). In different experiments, vaccination with SUB/AKR 
provided control for hard (Ixodes spp., Rhipicephalus spp., Amblyomma 
americanum, Dermacentor variabilis) and soft (Ornithodoros spp.) ticks, 
mosquitoes (Aedes albopictus), sand flies (Phlebotomus perniciosus), poultry 
red mites (Dermanyssus gallinae) and sea lice (Caligus rogercresseyi) 
infestations and tick infections with A. phagocytophilum, A. marginale, Babesia 
bigemina and Borrelia burgdorferi (de la Fuente et al., 2013; Merino et al., 
2013).  
These results suggested that vaccination with SUB reduces protein levels in 
feeding ticks by an unknown mechanism but probably mediated by antibody-
antigen interactions in the cell cytoplasm (de la Fuente et al., 2011), which 
affects SUB translocation to the nucleus and/or function as a transcriptional 
regulator of its own expression and of genes involved in several biological 
processes playing an important role in tick feeding and reproduction and in 
pathogen infection (de la Fuente et al., 2011; Merino et al., 2013). These results 
suggest that SUB/AKR could be used to develop a universal vaccine against 
multiple arthropod vectors (de la Fuente et al., 2011). However, the results of 
the vaccine trial with recombinant A. albopictus AKR failed to demonstrate a 
significant effect of mosquito SUB ortholog protein against R. sanguineus 
infestations in dogs (Canales et al., 2009). The observed trend towards 
reduction of oviposition and nymphal and larval infestations (Canales et al., 
2009) suggested that vaccination with R. sanguineus SUB might improve 
vaccine efficacy. In fact, in a preliminary unpublished trial, dogs living in the 
countryside (Alcolea de Calatrava, Spain) were vaccinated with SUB (two doses 
on weeks 1 and 5 and revaccinated a year after of the firstimmunization) by 
request oftheir owners.Animals were heavily infested with R. sanguineus. After 
vaccination many ticks did not complete feeding and animals remained 
protected (no need for acaricide treatment) for the next 24 months, suggesting 
that further experiments are required to evaluate the protective capacity of SUB 
vaccine against tick infestations in dogs.  
3.3 Bm86: The protective antigen, Bm86, was obtained from the gut of semi-
engorged Rhipicephalus (Boophilus) microplus adult female ticks (Rand et al., 
1989). This antigen has been the only antigenthus far to beused inmarketed 
vaccines for the control of ectoparasite infestations (de la Fuente et al., 2007). 
Use of the recombinant Bm86 gut antigen in commercial vaccine formulations 
protected against cattle ticks, R. microplus, R. annulatus and R. decoloratus 
infestations and conferred partial protection against phylogenetically related 
Hyalomma and Rhipicephalus spp., but failed to protect against the more 
phylogenetically distant Amblyomma spp. (de la Fuente and Kocan, 2003, 
2006). Perez-Perez et al. (2010) used Bm86 to vaccinate dogs experimentally 
infected with R. sanguineus larvae, nymphs and adults. The results showed a 
significant reduction in tick infestations for all instars and in female tick weight 
and oviposition, suggesting that vaccination with Bm86 could be used for the 
control of R. sanguineus infestations in dogs. Recently, a preliminary 
experiment in R. sanguineus demonstrated a synergistic effect of SUB and 
Bm86 knockdown (de la Fuente et al., 2006d), suggesting the possibility of 
combining these antigens to improve control of dog tick infestations. 
 
4. Tick paralysis  
Tick paralysis is not an infectious disease, but is worth briefly considering in this 
review because it is caused by ticks and it affects dogs and cats, livestock and 
in some cases, humans (Hall-Mendelin et al., 2011). This toxicosis is caused by 
neurotoxins produced by tick salivary glands and results in a rapidly ascending 
flaccid paralysis (HallMendelin et al., 2011). To protect against Ixodes 
holocyclus tick-induced paralysis, research has been directed towards 
developing a vaccine using a recombinant inactive form of the toxin (Masina 
and Broady, 1999; Bratu and Lutwick, 2002).  
However, other tick species such as R. sanguineus may also cause paralysis in 
dogs and thus require development of prevention measures (Otranto et al., 
2012).  
 
5. Conclusions  
Experiments with tick vaccines demonstrated that it is possible to controltick 
infestations using ectoparasite antigens. Commercial vaccines containing Bm86 
demonstrated the possibilities oftick vaccines as part ofintegrated control 
programs to reduce cattle tick populations while reducing acaricide applications 
to prevent selection of resistant ticks and contamination with chemical residues. 
Recent results suggestthat structurally and functionally conserved arthropod 
antigens could be used to confer protection against multiple vector species and 
pathogen infection. The few vaccination experiments reported in dogs also 
suggest that vaccines with arthropod-derived antigens may be effective for the 
control of vector infestations in pets. Recently, new candidate tick protective 
antigens have been discovered that offer new possibilities for developing 
vaccines for the control of tick infestations and pathogen infection in animals 
(Merino et al., 2013; Hajdusek ˇ et al., 2013). Taken together, these results 
suggest that effective vaccines for the control of vector infections and VBD of 
pets could be developed with vector-derived antigen(s) alone or in combination 
with pathogen-derived antigens using the information obtained from the 
molecular characterization of the host-vector-pathogen interface. 
 
